This is not the most recent version of the article. View current version (18 AUG 2016)

Intervention Review

You have free access to this content

Hormonal contraceptives for contraception in overweight or obese women

  1. Laureen M Lopez1,*,
  2. David A Grimes2,
  3. Mario Chen3,
  4. Conrad Otterness4,
  5. Carolyn Westhoff5,
  6. Alison Edelman6,
  7. Frans M Helmerhorst7

Editorial Group: Cochrane Fertility Regulation Group

Published Online: 30 APR 2013

Assessed as up-to-date: 4 FEB 2013

DOI: 10.1002/14651858.CD008452.pub3


How to Cite

Lopez LM, Grimes DA, Chen M, Otterness C, Westhoff C, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD008452. DOI: 10.1002/14651858.CD008452.pub3.

Author Information

  1. 1

    FHI 360, Clinical Sciences, Research Triangle Park, North Carolina, USA

  2. 2

    University of North Carolina, School of Medicine, Obstetrics and Gynecology, Chapel Hill, North Carolina, USA

  3. 3

    FHI 360, Division of Biostatistics, Research Triangle Park, North Carolina, USA

  4. 4

    FHI 360, Program Sciences, Research Triangle Park, North Carolina, USA

  5. 5

    Columbia University, Dept of Obstetrics and Gynecology, New York, New York, USA

  6. 6

    Oregon Health & Science University, Dept. of Obstetrics and Gynecology, Portland, Oregon, USA

  7. 7

    Leiden University Medical Center, Department of Gynaecology, Division of Reproductive Medicine and Dept. of Clinical Epidemiology, Leiden, Netherlands

*Laureen M Lopez, Clinical Sciences, FHI 360, P.O. Box 13950, Research Triangle Park, North Carolina, 27709, USA. llopez@fhi360.org.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

This is not the most recent version of the article. View current version (18 AUG 2016)

[Analysis 1.1]
Analysis 1.1. Comparison 1 COC: norgestimate 180/215/250 µg/ EE 25 or norethindrone acetate 1mg/EE 20 µg), Outcome 1 Relative risk of pregnancy by body weight or BMI.
[Analysis 1.2]
Analysis 1.2. Comparison 1 COC: norgestimate 180/215/250 µg/ EE 25 or norethindrone acetate 1mg/EE 20 µg), Outcome 2 Breakthrough bleeding or spotting with NGM/EE (cycle 6): weight (lb) >155 versus <=123.
[Analysis 1.3]
Analysis 1.3. Comparison 1 COC: norgestimate 180/215/250 µg/ EE 25 or norethindrone acetate 1mg/EE 20 µg), Outcome 3 Breakthrough bleeding or spotting with NGM/EE (cycle 6): weight (lb) >155 versus 124 to 155.
[Analysis 1.4]
Analysis 1.4. Comparison 1 COC: norgestimate 180/215/250 µg/ EE 25 or norethindrone acetate 1mg/EE 20 µg), Outcome 4 Breakthrough bleeding or spotting with NGM/EE (cycle 13): weight (lb) >155 versus <=123.
[Analysis 1.5]
Analysis 1.5. Comparison 1 COC: norgestimate 180/215/250 µg/ EE 25 or norethindrone acetate 1mg/EE 20 µg), Outcome 5 Breakthrough bleeding or spotting with NGM/EE (cycle 13): weight (lb) >155 versus 124 to 155.
[Analysis 1.6]
Analysis 1.6. Comparison 1 COC: norgestimate 180/215/250 µg/ EE 25 or norethindrone acetate 1mg/EE 20 µg), Outcome 6 Breakthrough bleeding or spotting with NETA/EE (cycle 6): weight (lb) >155 versus <=123.
[Analysis 1.7]
Analysis 1.7. Comparison 1 COC: norgestimate 180/215/250 µg/ EE 25 or norethindrone acetate 1mg/EE 20 µg), Outcome 7 Breakthrough bleeding or spotting with NETA/EE (cycle 6): weight (lb) >155 versus 124 to 155.
[Analysis 1.8]
Analysis 1.8. Comparison 1 COC: norgestimate 180/215/250 µg/ EE 25 or norethindrone acetate 1mg/EE 20 µg), Outcome 8 Breakthrough bleeding or spotting with NETA/EE (cycle 13): weight (lb) >155 versus <=123.
[Analysis 1.9]
Analysis 1.9. Comparison 1 COC: norgestimate 180/215/250 µg/ EE 25 or norethindrone acetate 1mg/EE 20 µg), Outcome 9 Breakthrough bleeding or spotting with NETA/EE (cycle 13): weight (lb) >155 versus 124 to 155.
[Analysis 2.1]
Analysis 2.1. Comparison 2 COC (extended regimen): levonorgestrel 100 µg + EE 20 µg, Outcome 1 Crude pregnancy rate by BMI group.
[Analysis 2.2]
Analysis 2.2. Comparison 2 COC (extended regimen): levonorgestrel 100 µg + EE 20 µg, Outcome 2 Pregnancies by BMI group.
[Analysis 2.3]
Analysis 2.3. Comparison 2 COC (extended regimen): levonorgestrel 100 µg + EE 20 µg, Outcome 3 Crude pregnancy rate by weight group.
[Analysis 2.4]
Analysis 2.4. Comparison 2 COC (extended regimen): levonorgestrel 100 µg + EE 20 µg, Outcome 4 Pregnancies by weight group.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Skin patch: norelgestromin 150 µg + EE 20 µg, Outcome 1 Pregnancies by body weight decile.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Vaginal ring: levonorgestrel 5 mg, Outcome 1 Discontinuation rate due to pregnancy at 12 months by body weight.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Vaginal ring: levonorgestrel 5 mg, Outcome 2 Pregnancy life-table rates by body weight.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Implant: 6-rod levonorgestrel 216 mg, Outcome 1 Cumulative pregnancy rates per 100 women by body weight.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Implant: 6-rod levonorgestrel 216 mg, Outcome 2 Annual pregnancy rates per 100 women by body weight.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Implant: 2-rod levonorgestrel 150 mg (original or with new elastomer), Outcome 1 Pregnancies by body weight.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Implant: single-rod etongestrel 68 mg, Outcome 1 Pregnancy rate per 100 woman-years by BMI group (3 years).
[Analysis 8.1]
Analysis 8.1. Comparison 8 Injectable: DMPA-SC 104 mg/0.65 mL, Outcome 1 Pregnancies at 1 year by BMI.